NCT00727415已完成1 期
A Prospective Multicenter Pilot Trial to Evaluate the Efficacy of a Treatment With Fludarabine, Cyclophosphamide, Lenalidomide (FCL) for Advanced Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 42
- 试验地点
- 23
- 主要终点
- Overall Complete Response (CR) Rate (Phase II)
研究概览
简要总结
This is a phase I - II multicenter, non-comparative, open label study in patients with previously treated CLL aimed at defining the MTD of Lenalidomide given in combination with Fludarabine, Cyclophosphamide and at evaluating the (CR) rate of FC given in combination with the MTD of Lenalidomide (FCL).
详细描述
OBJECTIVES:
Primary
- To define the maximum tolerated dose (MTD) of Lenalidomide given in combination with FC.(Phase I)
- To evaluate the complete remission (CR) rate of FC given in combination with the MTD of Lenalidomide (FCL). (Phase II)
Secondary
- To define the toxicity and the infection rate of patients treated with FCL and the median number of delivered courses of FCL, overall response rate and the progression-free survival and the relationship between the response and the baseline biologic factors (IgVH, FISH, ZAP-70, CD38).
- To evaluate the overall response rate (complete and partial responses).
- To evaluate the progression-free survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >=18 years.
- •Able to adhere to the study visit schedule and other protocol requirements.
- •Patients with advanced stage or progressive CLL (NCI criteria) and relapsed or refractory disease.
- •No more than 2 previous different treatment lines.
- •No treatment with Campath-1H in the previous 6 months.
- •Disease-free of prior malignancies for >=5 years, with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.
- •All previous cancer therapy, including chemotherapy, immunotherapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this study.
- •ECOG performance status of <=2 at study entry.
- •Laboratory test results within these ranges:
- •Serum creatinine <=1.5 mg/dL and creatinine clearance ≥60mL/min
- •Total bilirubin <=1.5 mg/dL
- •AST (SGOT) and ALT (SGPT) <=1.5 x ULN
- •Able to take low molecular weight heparin or in alternative, low- fixed-dose warfarin or, in alternative, low-dose aspirin.
- •Able to understand and voluntarily sign the informed consent form.
- •Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL 10 - 14 days prior to therapy and repeated within 24 hours of starting study. FCBP must agree to use two reliable forms of contraception for at least 28 days before starting study drug; while participating in the study; and for at least 4 weeks after discontinuation from the study.
- •Females must agree to abstain from breastfeeding during study participation and for at least 28 days after discontinuation from the study.
- •Males must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 4 weeks following discontinuation.
- •(Other details regarding pregnancy tests and contraception are reported in the chapter "Eligibility Criteria" within the study protocol).
排除标准
- •Treatment with Campath-1H during the previous 6 months.
- •Concurrent use of other anti-cancer agents.
- •Positive DAT with clinical and laboratory signs of hemolysis, autoimmune thrombocytopenia.
- •Known positivity for HIV or active infectious hepatitis.
- •Active bacterial, viral, or fungal infection requiring systemic anti-viral, antibiotic or anti-fungal therapy.
- •Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- •Pregnant or breast feeding females (lactating females must agree not to breast feed while taking Lenalidomide).
- •Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- •Prior history or presence of thrombosis, thromboembolism, hearth failure or arrhythmia, neurologic disease and renal insufficiency.
- •Use of any other experimental drug or therapy within 28 days of baseline.
- •Known hypersensitivity to thalidomide.
- •The development of erythema nodosum, desquamating rash while taking thalidomide or similar drugs.
- •Any prior use of Lenalidomide
- •Lactose intolerance
结局指标
主要结局
Overall Complete Response (CR) Rate (Phase II)
时间窗: After 6 months from study entry (end of treatment).
Response will be assessed by clinical examination, peripheral blood, bone marrow aspirate and biopsy, radiographic evaluation. Response will be evaluated at three different levels: clinical, cytometric and molecular.
Maximum Tolerated Dose of Lenalidomide (Phase I)
时间窗: The MTD of Lenalinomide will be evaluated during the two courses given with the escalated dose of Lenalinomide defined by the respective dose level.
Maximum tolerated dose of lenalidomide given in combination with fludarabine.
次要结局
- Correlation Between Complete Response (CR) and Baseline Biologic Parameters (i.e., IgHV, CD38, Etc.).(After 6 months from study entry (end of treatment).)
- Number of Patients Reaching Disease-free Survival (DSF) Overall(After 6 months from study entry (end of treatment))
- Toxicity as Assessed by NCI CTCAE v3.0(At 24 months from study entry (end of follow-up))
- Number of Patients With Severe Infections(At 24 months from study entry (end of follow-up))
研究者
研究点 (23)
Loading locations...
相似试验
已完成
1 期
Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple MyelomaRelapseRefractory Multiple MyelomaNCT00306813University of Wuerzburg53
已完成
1 期
A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid TumorDesmoid TumorNCT03802084Hyo Song Kim24
终止
2 期
BIBW 2992 (Afatinib) and VinorelbineCarcinoma Breast Stage IVNCT01531764University of Magdeburg2
已完成
2 期
Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)Marginal Zone B-cell LymphomaNCT01164267International Extranodal Lymphoma Study Group (IELSG)30
暂停
2 期
Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia PatientsLymphoid LeukemiaAcute Myeloid LeukemiaNCT02462265Oshadi Drug Administration15